I agree, just because SI is happy to go down with the ship...

I agree, just because SI is happy to go down with the ship doesn’t mean that the rest of them will follow.

I was shocked when the FDA knocked back the aGVHD application. Very disappointing for the team at MSB and for share holders. And to hear that their concern was with the ability to check and validate potency is a big cloud over the head of MSB. Especially since their phase 2 trials tended to not show a normal dose response curve (admittedly with low patient numbers).

I can imagine that stagnant revenue, looming loan deadlines, uncertainly over partnerships and probable capital raising would have been a pretty stressful proposition for a CFO. Especially with the MOA/potency called into question and the major phase 3 trials now published and unlikely to progress to FDA approval without more trials.

Pretty disappointing really. I have owned MSB shares in he past and luckily sold out prior to COVID at just over $3 when I got cold feet in relation to the then pending CHF trial results. I’d hoped to get back in once they had FDA approval and a good revenue stream but that seems further away than ever.